2013;84:489 95. S4.2.6-6. Costa J, Lopes CM. Barsheshet A, et al. Combined assessment of sex- and mutation-specific information for risk stratification in type 1 long QT syndrome. Heart Rhythm. 2012;9:892 8. S4.2.6-7. Hershberger RE, Lindenfeld J, Mestroni L, et al. Genetic evalua- tion of cardiomyopathy a Heart Failure Society of America practice guideline. J Cardiac Fail. 2009;15:83 97. S4.2.6-8. Kim JA, Lopes CM, Moss AJ, et al. Trigger-specific risk factors and response to therapy in long QT syndrome type 2. Heart Rhythm. 2010;7:1797 805. S4.2.6-9. Migdalovich D, Moss AJ, Lopes CM, et al. Mutation and gender- specific risk in type 2 long QT syndrome: implications for risk strati- fication for life-threatening cardiac events in patients with long QT syndrome. Heart Rhythm. 2011;8:1537 43. S4.2.6-10. Crotti L, Marcou CA, Tester DJ, et al. Spectrum and prevalence of muta- tions involving BrS1- through BrS12-susceptibility genes in a cohort of unrelated patients referred for Brugada syndrome genetic testing: implications for genetic testing. J Am Coll Cardiol. 2012;60:1410 8. S4.2.6-11. Probst V, Wilde AA, Barc J, et al. SCN5A mutations and the role of genetic background in the pathophysiology of Brugada syndrome. Circ Cardiovas Genetics. 2009;2:552 7. S4.2.6-12. Dintzis RZ. Genetic variation and the meiotic process. Res Publ Assoc Res Nerv Ment Dis. 1991;69:39 46. S4.2.6-13. Groeneweg JA, Bhonsale A, James CA, et al. Clinical presentation, long-term follow-up, and outcomes of 1001 arrhythmogenic right ventricular dysplasia/cardiomyopathy patients and family members. Circ Cardiovasc Genet. 2015;8:437 46. S4.2.6-14. Marcus FI, Edson S, Towbin JA. Genetics of arrhythmogenic right ventricular cardiomyopathy: a practical guide for physicians. J Am Coll Cardiol. 2013;61:1945 8. S4.2.6-15. Quarta G, Muir A, Pantazis A, et al. Familial evaluation in arrhyth- mogenic right ventricular cardiomyopathy: impact of genetics and revised task force criteria. Circulation. 2011;123:2701 9. S4.2.6-16. 